GLENMARK Stock Overview
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Glenmark Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,060.00 |
| 52 Week High | ₹1,070.00 |
| 52 Week Low | ₹500.35 |
| Beta | 0.88 |
| 1 Month Change | 12.81% |
| 3 Month Change | 22.18% |
| 1 Year Change | 107.03% |
| 3 Year Change | 85.44% |
| 5 Year Change | 66.56% |
| Change since IPO | 3,808.92% |
Recent News & Updates
Recent updates
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10Increases to Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Might Cool off for now
Sep 17Glenmark Pharmaceuticals' (NSE:GLENMARK) Dividend Will Be ₹2.50
Aug 27Shareholder Returns
| GLENMARK | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.6% | -2.2% | -2.1% |
| 1Y | 107.0% | 55.3% | 45.3% |
Return vs Industry: GLENMARK exceeded the Indian Pharmaceuticals industry which returned 54.9% over the past year.
Return vs Market: GLENMARK exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| GLENMARK volatility | |
|---|---|
| GLENMARK Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: GLENMARK has not had significant price volatility in the past 3 months.
Volatility Over Time: GLENMARK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 15,556 | Glenn Saldanha | www.glenmarkpharma.com |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors.
Glenmark Pharmaceuticals Limited Fundamentals Summary
| GLENMARK fundamental statistics | |
|---|---|
| Market cap | ₹299.12b |
| Earnings (TTM) | -₹7.64b |
| Revenue (TTM) | ₹131.58b |
2.3x
P/S Ratio-39.1x
P/E RatioIs GLENMARK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLENMARK income statement (TTM) | |
|---|---|
| Revenue | ₹131.58b |
| Cost of Revenue | ₹50.39b |
| Gross Profit | ₹81.19b |
| Other Expenses | ₹88.83b |
| Earnings | -₹7.64b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.08 |
| Gross Margin | 61.70% |
| Net Profit Margin | -5.81% |
| Debt/Equity Ratio | 53.2% |
How did GLENMARK perform over the long term?
See historical performance and comparison